Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease

By Vincent Wai-Sun Wong, J. Vergniol, G. Wong, J. Foucher, H. Chan, B. le Bail, P. Choi, M. Kowo, A. Chan, Wassil Merrouche and 2 more. Hepatology, 2010

1,296 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Physiology

View Paper: https://www.semanticscholar.org/paper/ed72cfc68a92507febe147e548b2f02a9f074235

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Hepatology

In Physiology

Asociacion Latinoamericana para el Estudio del Higado

Citations in the corpus

WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver. (2015, background): “So far, the number of studies that have investigated TE in NAFLD patients remains limited (Gaia et al. 2011; Nobili et al. 2008; Petta et al. 2011; Wong et al. 2010; Yoneda et al. 2008; Wong et al. 2012; Kumar et al. 2013).”
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. (2019, background): “3 HDL cholesterol (mg/dL) 351 43 [17] [15-101]”
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. (2015, background): “Journal of Hepatology 201 Recommendations • TE may be used to rule out severe fibrosis or cirrhosis in patients with ALD (B2) • Non-invasive assessment of fibrosis, using TE should be considered in patients with PBC or PSC (B2) • Follow-up assessment of liver fibrosis with TE should be performed in ”
EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version) (2017, background): “9 kPa, the sensitivity, specificity, PPV and NPV for F3 or greater disease are 91%, 75%, 52%, and 97%, respectively [55].”
Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. (2010, background): “Both tests showed a significant influence of steatosis on CAP values (p , 10210) but no significant influence of fibrosis evaluated as Metavir score for HCV and HBV patients (p 5 0.80) and Brunt score for ALD and NAFLD patients (p5 0.91).”
Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years (2010, background): “In an appropriate setting, patients with NAFLD can be motivated to exercise regularly and modify their lifestyle.32 33 In short-term studies, exercise intervention decreased both hepatic and visceral fat as measured by magnetic resonance spectroscopy.34 The future challenge is how to maintain health”
Accuracy of real‐time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: A pilot study (2012, result): “In this study, the correlation between liver stiffness values, assessed either with real-time SWE or TE, and fibrosis stage were not affected by steatosis or necroinflammation, which is in agreement with previous studies assessing liver elasticity with TE or MRE.8-10,33,34 However, most patients in ”